170 related articles for article (PubMed ID: 36996787)
21. Lymphocytosis after treatment with dasatinib in chronic myeloid leukemia: Effects on response and toxicity.
Schiffer CA; Cortes JE; Hochhaus A; Saglio G; le Coutre P; Porkka K; Mustjoki S; Mohamed H; Shah NP
Cancer; 2016 May; 122(9):1398-407. PubMed ID: 26998677
[TBL] [Abstract][Full Text] [Related]
22. Treatment-, patient-, and disease-related factors and the emergence of adverse events with tyrosine kinase inhibitors for the treatment of chronic myeloid leukemia.
Irvine E; Williams C
Pharmacotherapy; 2013 Aug; 33(8):868-81. PubMed ID: 23553655
[TBL] [Abstract][Full Text] [Related]
23. Expression of LYN and PTEN genes in chronic myeloid leukemia and their importance in therapeutic strategy.
Ferri C; Bianchini M; Bengió R; Larripa I
Blood Cells Mol Dis; 2014; 52(2-3):121-5. PubMed ID: 24091144
[TBL] [Abstract][Full Text] [Related]
24. Dasatinib: a tyrosine kinase inhibitor for the treatment of chronic myelogenous leukemia and philadelphia chromosome-positive acute lymphoblastic leukemia.
Steinberg M
Clin Ther; 2007 Nov; 29(11):2289-308. PubMed ID: 18158072
[TBL] [Abstract][Full Text] [Related]
25. Unexpected pancytopenia: Dasatinib induced aplastic anemia in chronic myeloid leukemia.
Feld J; Steinberg A; El Jamal SM; Shapira I
J Oncol Pharm Pract; 2022 Jan; 28(1):232-236. PubMed ID: 34152210
[TBL] [Abstract][Full Text] [Related]
26. Pleural Effusion in Dasatinib-Treated Patients With Chronic Myeloid Leukemia in Chronic Phase: Identification and Management.
Cortes JE; Jimenez CA; Mauro MJ; Geyer A; Pinilla-Ibarz J; Smith BD
Clin Lymphoma Myeloma Leuk; 2017 Feb; 17(2):78-82. PubMed ID: 28082112
[TBL] [Abstract][Full Text] [Related]
27. The efficacy of tolvaptan in treating dasatinib-induced pleural effusions in patients with chronic myelogenous leukemia.
Aoyama R; Ishikawa J; Harada K
J Cardiol; 2020 Feb; 75(2):203-207. PubMed ID: 31416783
[TBL] [Abstract][Full Text] [Related]
28. Dasatinib in imatinib-resistant or -intolerant chronic-phase, chronic myeloid leukemia patients: 7-year follow-up of study CA180-034.
Shah NP; Rousselot P; Schiffer C; Rea D; Cortes JE; Milone J; Mohamed H; Healey D; Kantarjian H; Hochhaus A; Saglio G
Am J Hematol; 2016 Sep; 91(9):869-74. PubMed ID: 27192969
[TBL] [Abstract][Full Text] [Related]
29. Management and Risk Factors for Pleural Effusion in Japanese Patients with Chronic Myeloid Leukemia Treated with First-line Dasatinib in Real-world Clinical Practice.
Tsuchiya S; Takaku T; Watanabe N; Iriyama N; Kimura Y; Iwanaga E; Sugimoto KJ; Mitsumori T; Ishikawa M; Nakazato T; Fujita H; Sato E; Hatta Y; Asou N; Kizaki M; Tokuhira M; Ando M; Kawaguchi T
Intern Med; 2023 Nov; 62(22):3299-3303. PubMed ID: 37005261
[TBL] [Abstract][Full Text] [Related]
30. HIV-associated Kaposi sarcoma and related diseases.
Gonçalves PH; Uldrick TS; Yarchoan R
AIDS; 2017 Sep; 31(14):1903-1916. PubMed ID: 28609402
[TBL] [Abstract][Full Text] [Related]
31. Clinical Efficacy and Safety of First-Line Dasatinib Therapy and the Relevance of Velocity of BCR-ABL1 Transcript Decline for Achievement of Molecular Responses in Newly Diagnosed Chronic-Phase Chronic Myeloid Leukemia: Report from the Juntendo Yamanashi Cooperative Study Group.
Takaku T; Iriyama N; Mitsumori T; Sato E; Gotoh A; Kirito K; Noguchi M; Koike M; Sakamoto J; Oba K; Komatsu N
Oncology; 2018; 94(2):85-91. PubMed ID: 29151104
[TBL] [Abstract][Full Text] [Related]
32. Extracavitary KSHV-associated large B-Cell lymphoma: a distinct entity or a subtype of primary effusion lymphoma? Study of 9 cases and review of an additional 43 cases.
Pan ZG; Zhang QY; Lu ZB; Quinto T; Rozenvald IB; Liu LT; Wilson D; Reddy V; Huang Q; Wang HY; Ren YS
Am J Surg Pathol; 2012 Aug; 36(8):1129-40. PubMed ID: 22790853
[TBL] [Abstract][Full Text] [Related]
33. Multiple remissions of extracavitary primary effusion lymphoma treated with a single cycle of liposomal doxorubicin in a patient infected with HIV.
Chen J; Mehraj V; Szabo J; Routy B; Michel RP; Routy JP
Curr Oncol; 2018 Dec; 25(6):e592-e596. PubMed ID: 30607128
[TBL] [Abstract][Full Text] [Related]
34. Real-life comparison of severe vascular events and other non-hematological complications in patients with chronic myeloid leukemia undergoing second-line nilotinib or dasatinib treatment.
Gora-Tybor J; Medras E; Calbecka M; Kolkowska-Leśniak A; Ponikowska-Szyba E; Robak T; Jamroziak K
Leuk Lymphoma; 2015; 56(8):2309-14. PubMed ID: 25563556
[TBL] [Abstract][Full Text] [Related]
35. Sequential use of second-generation tyrosine kinase inhibitors following imatinib therapy in pediatric chronic myeloid leukemia: A report from the Japanese Pediatric Leukemia/Lymphoma Study Group.
Kurosawa H; Tanizawa A; Muramatsu H; Tono C; Watanabe A; Shima H; Ito M; Yuza Y; Hamamoto K; Hotta N; Okada M; Saito AM; Manabe A; Mizutani S; Adachi S; Horibe K; Ishii E; Shimada H
Pediatr Blood Cancer; 2018 Dec; 65(12):e27368. PubMed ID: 30084127
[TBL] [Abstract][Full Text] [Related]
36. Successful treatment of follicular lymphoma with second-generation tyrosine kinase inhibitors administered for coexisting chronic myeloid leukemia.
Fujiwara SI; Shirato Y; Ikeda T; Kawaguchi SI; Toda Y; Ito S; Ochi SI; Nagayama T; Mashima K; Umino K; Minakata D; Nakano H; Morita K; Yamasaki R; Kawasaki Y; Sugimoto M; Ashizawa M; Yamamoto C; Hatano K; Sato K; Oh I; Ohmine K; Muroi K; Kanda Y
Int J Hematol; 2018 Jun; 107(6):712-715. PubMed ID: 29185155
[TBL] [Abstract][Full Text] [Related]
37. Cardiovascular care of patients with chronic myeloid leukemia (CML) on tyrosine kinase inhibitor (TKI) therapy.
Barber MC; Mauro MJ; Moslehi J
Hematology Am Soc Hematol Educ Program; 2017 Dec; 2017(1):110-114. PubMed ID: 29222244
[TBL] [Abstract][Full Text] [Related]
38. Combination of axitinib with dasatinib improves the outcome of a chronic myeloid leukemia patient with BCR-ABL1 T315I mutation.
Deng Q; Wang E; Wu X; Cheng Q; Liu J; Li X
Zhong Nan Da Xue Xue Bao Yi Xue Ban; 2020 Jul; 45(7):874-880. PubMed ID: 32879093
[TBL] [Abstract][Full Text] [Related]
39. Finding the right BCR-ABL1 tyrosine kinase inhibitor: a case report of successful treatment of a patient with chronic myeloid leukemia and a V299L mutation using nilotinib.
Elnair R; Galal A
BMC Cancer; 2018 Nov; 18(1):1097. PubMed ID: 30419862
[TBL] [Abstract][Full Text] [Related]
40. Human herpesvirus-8 (HHV-8)-associated primary effusion lymphoma in two renal transplant recipients receiving rapamycin.
Boulanger E; Afonso PV; Yahiaoui Y; Adle-Biassette H; Gabarre J; Agbalika F
Am J Transplant; 2008 Mar; 8(3):707-10. PubMed ID: 18261181
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]